SCHEDULE: FMR LLC Discloses 4.0% Stake in Apogee Therapeutics

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 4.0% of Apogee Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson, through various affiliated entities, have filed a Schedule 13G, indicating a beneficial ownership of 2,493,136.73 shares of Apogee Therapeutics Inc. common stock.
• This holding represents 4.0% of the total outstanding common stock of Apogee Therapeutics Inc. as of June 30, 2026.
• The filing is an amendment (Amendment No. 4) to a previous filing.
• FMR LLC is identified as a 'HC' (likely Holding Company or similar) type of reporting person, while Abigail P. Johnson is identified as an 'IN' (likely Investor or similar) type of reporting person.
• The filing confirms that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as a significant stake held by a major investment firm like FMR LLC suggests confidence in the company's long-term prospects.

Positives

• FMR LLC and Abigail P. Johnson have a significant beneficial ownership stake of 4.0% in Apogee Therapeutics Inc., indicating confidence in the company's prospects.
• The reporting persons are established entities, suggesting a stable and long-term investment approach.

Negatives

• The filing does not contain any negative financial results or operational challenges for Apogee Therapeutics Inc. as it is a Schedule 13G filing focused on ownership.

Risks

• As a Schedule 13G filing, it primarily reports ownership and does not detail specific risks related to Apogee Therapeutics Inc.'s operations or market position.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Apogee Therapeutics Inc. itself. The future outlook for Apogee Therapeutics Inc. would be found in other SEC filings by the company.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by FMR LLC and Abigail P. Johnson indicates a significant institutional investment in Apogee Therapeutics Inc., a company likely operating in the biotechnology or pharmaceutical sector. Such filings often signal sustained interest from major investors.

Stakeholder Impact

• Shareholders: The significant stake by FMR LLC may be viewed positively, potentially indicating increased institutional support and stability.
• Management of Apogee Therapeutics Inc.: The filing confirms a substantial investor, which could influence strategic discussions.
• Potential Investors: The disclosure may attract further investor interest due to the validation from a large investment firm.

Next Steps

• Filing of subsequent amendments to Schedule 13G if beneficial ownership changes significantly.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide operational or financial results of Apogee Therapeutics Inc. While the significant stake by FMR LLC is a positive indicator of institutional confidence, it does not offer sufficient information to make a buy or sell recommendation. A 'hold' recommendation is appropriate pending further company-specific disclosures.

Keywords

Apogee Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Biotechnology